The South African Tuberculosis Vaccine Initiative (SATVI) is an accredited UCT Research Site which offers major benefits to the organisation, including improved governance environment, five-yearly cycle of strategic review, and the potential to leverage additional funding for students and post-doctoral fellows. SATVI recently published the findings of the first efficacy trial of a new infant TB vaccine (MVA85A) in almost 50 years (Tameris/Hatherill, Lancet 2013).
Keyword results: SATVI
The South African Tuberculosis Vaccine Initiative (SATVI) invites applications for the vacancy of Research Officer (Clinical). Closing Date: 31 January 2016.